Meeting Details

The 31st Annual General Meeting of Nectar Lifesciences Limited was held on Friday, September 18, 2026, at 11:00 A.M. through Video Conferencing/Other Audio-Visual Means. The venue of the meeting was deemed to be at the Registered Office of the Company at Showroom no. 8, First Floor, Patiala Complex, Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab- 140 507. The meeting commenced at 11:00 A.M. and concluded at 11:25 A.M. IST.

Directors and Attendees Present

Directors Present (All through VC):

  • Mr. Sanjiv Goyal - Chairman & Managing Director
  • Dr. Indu Pal Kaur - Independent Director
  • Dr. Kuldip Kumar Bhasin - Independent Director and Chairperson of Stakeholders Relationship Committee
  • Dr. Rupinder Tewari - Independent Director and Chairperson of Audit Committee and Nomination & Remuneration Committee
  • Mr. Sushil Kapoor - Whole-time Director & Chief Financial Officer
  • Dr. Gunmala Suri - Non-Executive Non-Independent Director

In Attendance (All through VC):

  • Mr. Sanjaymohan Singh Rawat - Company Secretary
  • Mr. Deepak Jindal - Partner of M/s. Deepak Jindal & Co., Chartered Accountants, Statutory Auditors
  • Mr. Prince Chadha - Secretarial Auditors & Scrutinizer
  • 49 Members through VC

Summary of Proposed Resolutions

The AGM considered and voted on five resolutions:

Item No. 1: To receive, consider and adopt the Standalone Financial Statements of the Company for the financial year ended March 31, 2026, and the Reports of the Board of Directors and Auditors thereon and Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, and the Report of Auditors thereon. (Ordinary Resolution)

Item No. 2: To appoint a director in place of Mr. Sanjiv Goyal (DIN- 00002841), who retires by rotation and being eligible, offers himself for re-appointment. (Ordinary Resolution)

Item No. 3: To consider and approve the re-appointment of Dr. Kuldip Kumar Bhasin (DIN-09250008) as an Independent Director for the second term of consecutive five years. (Special Resolution)

Item No. 4: To consider and approve the re-appointment of Dr. Indu Pal Kaur (DIN-09686862) as an Independent Director for the second term of consecutive five years. (Special Resolution)

Item No. 5: To consider and approve the appointment of Dr. Gunmala Suri (DIN-11879344) as a Non-Executive Non-Independent Director of the Company. (Ordinary Resolution)

Voting Process and Methods

The Company provided remote e-voting facilities through KFIN Technologies Limited available to members from September 15, 2026 (9:00 A.M. IST) to September 17, 2026 (5:00 P.M. IST). Members who had not cast their votes through remote e-voting had the opportunity to cast their votes during the meeting through the e-voting system provided by KFIN. There was no voting by show of hands.

The Board of Directors appointed Prince Chadha, Proprietor of P. Chadha & Associates, Company Secretaries, Chandigarh, as the scrutinizer to supervise the e-voting process.

Key Voting Outcomes

All five resolutions were passed with requisite majority. The detailed voting results are as follows:

Resolution 1 - Adoption of Financial Statements:

  • Promoter and Promoter Group: 100,706,448 votes in favor (100.00%), 0 against (0.00%)
  • Public - Institutional Holders: 889,678 votes in favor (100.00%), 0 against (0.00%)
  • Public - Others: 50,337 votes in favor (77.91%), 14,271 against (22.08%)
  • Total: 101,646,467 votes in favor (99.986%), 14,271 against (0.014%)

Resolution 2 - Re-appointment of Mr. Sanjiv Goyal:

  • Promoter and Promoter Group: 100,706,448 votes in favor (100.00%), 0 against (0.00%)
  • Public - Institutional Holders: 889,678 votes in favor (100.00%), 0 against (0.00%)
  • Public - Others: 30,246 votes in favor (46.81%), 34,362 against (53.18%)
  • Total: 101,626,376 votes in favor (99.9662%), 34,362 against (0.0338%)

Resolution 3 - Re-appointment of Dr. Kuldip Kumar Bhasin:

  • Promoter and Promoter Group: 100,706,448 votes in favor (100.00%), 0 against (0.00%)
  • Public - Institutional Holders: 889,678 votes in favor (100.00%), 0 against (0.00%)
  • Public - Others: 30,246 votes in favor (46.81%), 34,362 against (53.18%)
  • Total: 101,626,376 votes in favor (99.9662%), 34,362 against (0.0338%)

Resolution 4 - Re-appointment of Dr. Indu Pal Kaur:

  • Promoter and Promoter Group: 100,706,448 votes in favor (100.00%), 0 against (0.00%)
  • Public - Institutional Holders: 889,678 votes in favor (100.00%), 0 against (0.00%)
  • Public - Others: 30,246 votes in favor (46.81%), 34,362 against (53.18%)
  • Total: 101,626,376 votes in favor (99.9662%), 34,362 against (0.0338%)

Resolution 5 - Appointment of Dr. Gunmala Suri:

  • Promoter and Promoter Group: 100,706,448 votes in favor (100.00%), 0 against (0.00%)
  • Public - Institutional Holders: 889,678 votes in favor (100.00%), 0 against (0.00%)
  • Public - Others: 30,246 votes in favor (46.81%), 34,362 against (53.18%)
  • Total: 101,626,376 votes in favor (99.9662%), 34,362 against (0.0338%)

Scrutinizer's Role and Findings

Prince Chadha, Proprietor of P. Chadha & Associates, Company Secretaries, Chandigarh, was appointed as the scrutinizer to supervise the e-voting process. The scrutinizer's consolidated report formed the basis for the voting results announcement. The results were placed on the website of the Company and on the website of KFIN.

Compliance with Laws and Regulations

The meeting was conducted in compliance with General Circular No. 14/2020 dated April 8, 2020, General Circular No. 17/2020 dated April 13, 2020, General Circular No. 20/2020 dated May 5, 2020 read with other relevant circulars, the latest being General Circular No. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs and other applicable provisions of the Companies Act, 2013 read with Rules made thereunder and the SEBI LODR Regulations and the Secretarial Standard-2 on General Meetings.

The Statutory Auditors, M/s Deepak Jindal & Co., Chartered Accountants, and Secretarial Auditor, P. Chadha & Associates, expressed unqualified opinion in their respective audit reports for the financial year 2025-2026 with no qualifications, observations or adverse comments.